Sanofi’s hurried,$2.5B pursuit for Synthorx drove buyout price high and left keen rival sorely disappointed

Sanofi was locked in a bidding war right up to the final moments of closing its $2.5 billion buyout of Synthorx, as it rushed to complete a deal — this or another — to bolster CEO Paul Hudson’s new R&D vision before wrapping the year. By Synthorx’s account, what began

Read the full article here

Related Articles